biostudies-literatureQuindos GEusko Jaurlaritza906563https://www.ebi.ac.uk/biostudies/studies/S-EPMC9149255biostudies-literatureUnknown12<h4>Background</h4>Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.<h4>Objective</h4>The aim of this study was to assess the <i>in vitro</i> activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of <i>Candida</i>.<h4>Methods</h4>Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 <i>Candida albicans</i>, 108 <i>Candida parapsilosis</i>, 60 <i>Candida glabrata</i>, 40 <i>Candida tropicalis</i>, 29 <i>Candida krusei</i>, 20 <i>Candida orthopsilosis</i>, 6 <i>Candida guilliermondii</i>, 2 <i>Candida famata</i>, 2 <i>CanFrontiers in cellular and infection microbiology<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study.PMC9149255Consejería de Educación, Universidades e Investigación del Gobierno Vasco (GIC15 IT-990-16)Guridi AEzpeleta GGuarro JMiranda-Cadena KMarcos-Arias CQuindos GSanchez-Reus FHamprecht ARomeo OPais CRodriguez-Iglesias MAEraso ELinares-Sicilia MJMachuca-Barcena JRezusta ABorroto-Esoda KSan-Millan RLopez-Soria LAngulo DRuiz-Gaitan ACastro-Mendez CVidal-Garcia MLorenzo DPereira JTortorano AMJauregizar NCapilla JMontesinos IMartin-Mazuelos EPeman JPrigitano AFernandez-Rivero MCanton Efalse<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study.<h4>Background</h4>Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.<h4>Objective</h4>The aim of this study was to assess the <i>in vitro</i> activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of <i>Candida</i>.<h4>Methods</h4>Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 <i>Candida albicans</i>, 108 <i>Candida parapsilosis</i>, 60 <i>Candida glabrata</i>, 40 <i>Candida tropicalis</i>, 29 <i>Candida krusei</i>, 20 <i>Candida orthopsilosis</i>, 6 <i>Candida guilliermondii</i>, 2 <i>Candida famata</i>, 2 <i>Can2022-01-01T00:00:00Z20222025-04-26T07:31:44.088Z2025-04-06T12:17:23.907ZS-EPMC91492553565175510.3389/fcimb.2022.906563